» Articles » PMID: 22429643

Usefulness of Health Registries when Estimating Vaccine Effectiveness During the Influenza A(H1N1)pdm09 Pandemic in Norway

Overview
Journal BMC Infect Dis
Publisher Biomed Central
Date 2012 Mar 21
PMID 22429643
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: During the 2009-2010 pandemic in Norway, 12 513 laboratory-confirmed cases of pandemic influenza A(H1N1)pdm09, were reported to the Norwegian Surveillance System for Communicable Diseases (MSIS). 2.2 million persons (45% of the population) were vaccinated with an AS03-adjuvanted monovalent vaccine during the pandemic. Most of them were registered in the Norwegian Immunisation Registry (SYSVAK). Based on these registries, we aimed at estimating the vaccine effectiveness (VE) and describing vaccine failures during the pandemic in Norway, in order to evaluate the role of the vaccine as a preventive measure during the pandemic.

Methods: We conducted a population-based retrospective cohort study, linking MSIS and SYSVAK with pandemic influenza vaccination as exposure and laboratory-confirmed pandemic influenza as outcome. We measured VE by week and defined two thresholds for immunity; eight and 15 days after vaccination.

Results: The weekly VE ranged from 77% to 96% when considering 15 days or more after vaccination as the threshold of immunity and from 73% to 94% when considering eight days or more. Overall, 157 individuals contracted pandemic influenza eight or more days after vaccination (8.4/100,000 vaccinated), of these 58 had onset 15 days or more after vaccination (3.0/100,000 vaccinated). Most of the vaccine failures occurred during the first weeks of the vaccination campaign. More than 30% of the vaccine failures were found in people below 10 years of age.

Conclusions: Having available health registries with data regarding cases of specific disease and vaccination makes it feasible to estimate VE in a simple and rapid way. VE was high regardless the immunity threshold chosen. We encourage public health authorities in other countries to set up such registries. It is also important to consider including information on underlying diseases in registries already existing, in order to make it feasible to conduct more complete VE estimations.

Citing Articles

Antibody levels in a cohort of pregnant women after the 2009 influenza A(H1N1) pandemic: Waning and association with self-reported severity and duration of illness.

Tunheim G, Laake I, Robertson A, Waalen K, Hungnes O, Naess L Influenza Other Respir Viruses. 2018; 13(2):191-200.

PMID: 30536590 PMC: 6379636. DOI: 10.1111/irv.12623.


Are children with special risk medical conditions receiving influenza vaccination? Validity of parental and provider report, and to a National Immunisation Register.

Tuckerman MPH J, Crawford N, Lynch J, Marshall H Hum Vaccin Immunother. 2018; 15(4):951-958.

PMID: 30507331 PMC: 6628868. DOI: 10.1080/21645515.2018.1554966.


Risk of pregnancy complications and adverse birth outcomes after maternal A(H1N1)pdm09 influenza: a Norwegian population-based cohort study.

Laake I, Tunheim G, Robertson A, Hungnes O, Waalen K, Haberg S BMC Infect Dis. 2018; 18(1):525.

PMID: 30348103 PMC: 6196446. DOI: 10.1186/s12879-018-3435-8.


Effectiveness of pandemic and seasonal influenza vaccines in preventing laboratory-confirmed influenza in adults: a clinical cohort study during epidemic seasons 2009-2010 and 2010-2011 in Finland.

Syrjanen R, Jokinen J, Ziegler T, Sundman J, Lahdenkari M, Julkunen I PLoS One. 2014; 9(9):e108538.

PMID: 25265186 PMC: 4180439. DOI: 10.1371/journal.pone.0108538.


Influenza A(H1N1)pdm09 virus infection in Norwegian swine herds 2009/10: the risk of human to swine transmission.

Grontvedt C, Er C, Gjerset B, Hauge A, Brun E, Jorgensen A Prev Vet Med. 2013; 110(3-4):429-34.

PMID: 23490143 PMC: 7132443. DOI: 10.1016/j.prevetmed.2013.02.016.

References
1.
Hardelid P, Fleming D, McMenamin J, Andrews N, Robertson C, Sebastianpillai P . Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A(H1N1)2009 infection in England and Scotland 2009-2010. Euro Surveill. 2011; 16(2). View

2.
Emborg H, Krause T, Hviid A, Simonsen J, Molbak K . Effectiveness of vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases: cohort study, Denmark, 2009-10. BMJ. 2012; 344:d7901. DOI: 10.1136/bmj.d7901. View

3.
Simpson C, Ritchie L, Robertson C, Sheikh A, McMenamin J . Vaccine effectiveness in pandemic influenza - primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine. Health Technol Assess. 2010; 14(34):313-46. DOI: 10.3310/hta14340-05. View

4.
Wichmann O, Stocker P, Poggensee G, Altmann D, Walter D, Hellenbrand W . Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010. Euro Surveill. 2010; 15(18). View

5.
Osterholm M, Kelley N, Sommer A, Belongia E . Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2011; 12(1):36-44. DOI: 10.1016/S1473-3099(11)70295-X. View